Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

BIOA

NASDAQ

BioAge Labs (BIOA)

4.28 USD −9.23% vs prior close Nov 20, 2026
BioAge Labs, Inc. price graph
64 sessions
12 4 24 Aug 20 Nov

The line runs 9.38 USD on 24 August through 4.28 USD on 20 November, on a scale from 4 to 12. Days the market did not trade hold the previous close, flat.

Market cap
196.7M USD
Revenue, year to Dec 2025
9.0M USD
EPS, diluted, year to Dec 2025
−2.24 USD
Avg volume
43.4K

as of Nov 20, 2026

Have BioAge Labs (BIOA) insiders bought or sold shares recently?

BIOA's newest Form 4 filing is dated 30 June 2026: none in the last 90 days.

Form 4

Have BioAge Labs (BIOA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
30 Jun 2026Barton ShanePrincipal Accounting OfficerSell20,216509K USD
29 Jun 2026Barton ShanePrincipal Accounting OfficerSell42,3501.1M USD
01 Apr 2026RUBIN PAUL DChief Medical OfficerSell8,820157K USD
02 Mar 2026RUBIN PAUL DChief Medical OfficerSell7,433151K USD
02 Feb 2026RUBIN PAUL DChief Medical OfficerSell7,433139K USD
13 Jan 2026GOLDSTEIN DOV A MDChief Financial OfficerSell27,000532K USD
13 Jan 2026Fortney KristenChief Executive OfficerSell233,1074.2M USD
02 Jan 2026RUBIN PAUL DChief Medical OfficerSell7,43395K USD
09 Dec 2025RUBIN PAUL DChief Medical OfficerSell18,000216K USD
04 Dec 2025RUBIN PAUL DChief Medical OfficerSell68,897702K USD
Sold10 open-market sales440,689$7.79M
13 other filings: grants, exercises, tax withholding and transfers, not trades
Have BioAge Labs (BIOA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
30 Jun 2026Barton ShanePrincipal Accounting OfficerOption exercise20,216132K USD
29 Jun 2026Barton ShanePrincipal Accounting OfficerOption exercise39,718263K USD
23 Apr 2026GOLDSTEIN DOV A MDChief Financial OfficerOption exercise3,54216K USD
01 Apr 2026RUBIN PAUL DChief Medical OfficerOption exercise8,82045K USD
02 Mar 2026RUBIN PAUL DChief Medical OfficerOption exercise7,43335K USD
01 Mar 2026GOLDSTEIN DOV A MDChief Financial OfficerOption exercise3,54216K USD
02 Feb 2026RUBIN PAUL DChief Medical OfficerOption exercise7,43335K USD
01 Feb 2026GOLDSTEIN DOV A MDChief Financial OfficerOption exercise3,54116K USD
16 Jan 2026GOLDSTEIN DOV A MDChief Financial OfficerOption exercise3,54216K USD
13 Jan 2026GOLDSTEIN DOV A MDChief Financial OfficerOption exercise27,000227K USD
02 Jan 2026RUBIN PAUL DChief Medical OfficerOption exercise7,43335K USD
09 Dec 2025RUBIN PAUL DChief Medical OfficerOption exercise18,000118K USD

Showing the 12 most recent of 13 compensation filings in this window. The figures above count all of them.

Which funds hold BioAge Labs (BIOA)?

8 of the 45 institutional funds we track reported a BioAge Labs position for the quarter ended 30 Sep 2026 — a combined 21.4M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold BioAge Labs (BIOA)?
FundPositionSharesValueShares q/q
D. E. Shaw & Co.Added1,156,4048.2M USD+55.7%
Millennium ManagementAdded636,5464.5M USD+185.9%
Renaissance TechnologiesAdded626,6614.4M USD+278.2%
Two Sigma InvestmentsAdded221,7141.6M USD+261.1%
AQR Capital ManagementAdded182,3781.3M USD+256.3%
Man GroupAdded127,103901K USD+600.4%
Citadel AdvisorsTrimmed41,538295K USD−47.0%
Balyasny Asset ManagementTrimmed30,519216K USD−95.7%
Marshall WaceExited

What has been filed or recorded for BioAge Labs (BIOA)?

The filings we hold for BioAge Labs, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for BioAge Labs (BIOA)?
And
13 Oct 2026Fails to deliverShares failed to deliver9,800 shares58K USD notional · 0.021% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.73 USDRevenue $0M
30 Sep 2026FinancialsTotal assets367.6M USDat period end
30 Sep 2026FinancialsTotal equity346.4M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.58 USDRevenue $2M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.52 USDRevenue $3M
31 Dec 2025Annual reportFY 2025 reportedEPS −2.24 USDRevenue $9M
31 Dec 2025FinancialsRevenue9.0M USDfiscal year
31 Dec 2025FinancialsNet income−80.6M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−2.24 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.56 USDRevenue $2M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.60 USDRevenue $2M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.36 USDRevenue $1M
31 Dec 2024Annual reportFY 2024 reportedEPS −6.63 USD

What do people ask about BioAge Labs (BIOA)?

From live data
What did BioAge Labs shares close at?4.28

BioAge Labs closed at 4.28 USD on 20 Nov 2026, down 9.23% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is BioAge Labs’ market cap?196.7M

BioAge Labs is worth 196.7M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is BioAge Labs’ revenue?9.0M

BioAge Labs reported revenue of 9.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have BioAge Labs insiders bought or sold shares recently?

No BioAge Labs insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 30 Jun 2026 (SEC Form 4). See Insiders

Which funds own BioAge Labs?8 of 45

8 of the 45 funds we track reported a BioAge Labs position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Millennium Management and Renaissance Technologies. See Funds

When did BioAge Labs last report earnings?−0.73

BioAge Labs last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.73 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words